|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.055 USD | 0.00% |
|
0.00% | -43.30% |
| 2023 | Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| 2022 | Remedent, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022 | CI |
Remedent, Inc. reported earnings results for the nine months ended December 31, 2015. Net sales for the nine months ended December 31, 2015 are EUR 2,095,353 as compared to EUR 2,151,377 for the nine months ended December 31, 2014. Net income for the nine months ended December 31, 2015 increased to $274,948 as compared to $148,642 for the nine months ended December 31, 2014.
The increase of 84.97% is due to improved pricing and reduced costs.
| 1st Jan change | Capi. | |
|---|---|---|
| -43.30% | 1.06M | |
| -7.16% | 177B | |
| -4.86% | 65.54B | |
| -4.28% | 47.09B | |
| +10.32% | 43.43B | |
| +8.14% | 41.77B | |
| +15.76% | 29.55B | |
| +15.53% | 24.83B | |
| -5.88% | 23.97B | |
| -5.38% | 23.54B |
REMEDENT, INC. 
